Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. These leading UK centers are in London, Edinburgh, Birmingham, and Dundee in addition to eight French centers.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

The Pharma Data

JULY 29, 2021

Gilead presented additional lenacapavir clinical development program data at the International AIDS Society (“IAS”) 2021 Conference on HIV Science. Kite announced a purchase agreement with BioNTech SE to acquire Kite’s solid tumor neoantigen T cell receptor R&D platform and clinical manufacturing facility in Gaithersburg, Maryland.

Sales 52

Sales Production FDA Approval Development 52

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. We expect this field to grow significantly in the coming years as these and other earlier stage assets are developed. Here are their answers.

Research 52

Research Drugs Protein RNA 52

The Pharma Data

OCTOBER 27, 2020

Under the agreement, during the option period, Molecular Partners will conduct Phase 1 clinical trials for MP0420, expected to begin in November 2020, and perform all remaining preclinical work for MP0423 and Novartis will conduct Phase 2 and Phase 3 clinical trials, with Molecular Partners as sponsor of these trials.

Development 52

Development Protein Manufacturing Medicine 52

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. “I

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52

XTalks

SEPTEMBER 14, 2020

The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. Xtalks has hosted some excellent webinars on navigating development and operations during the current pandemic, presented by leading experts in the pharmaceutical, biotechnology and food industries.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92